Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

JOURNAL ARTICLE published June 2006 in Gynecologic Oncology

Authors: Maurie Markman | John Blessing | Stephen C. Rubin | Joseph Connor | Parviz Hanjani | Steven Waggoner